Indoximod
- Generic Name
- Indoximod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H14N2O2
- CAS Number
- 110117-83-4
- Unique Ingredient Identifier
- TX5CYN1KMZ
- Background
Indoximod has been used in trials studying the treatment of Glioma, Melanoma, Ependymoma, Gliosarcoma, and Lung Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: 1-methyl-d-tryptophanDrug: docetaxelOther: diagnostic laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01191216
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Billings Clinic, Billings, Montana, United States
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00567931
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath